Search

Your search keyword '"Le Houssine, P"' showing total 18 results
Start Over Author "Le Houssine, P"
18 results on '"Le Houssine, P"'

1. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Author

Gaborit, Benjamin, Vanhove, Bernard, Vibet, Marie-Anne, Le Thuaut, Aurélie, Lacombe, Karine, Dubee, Vincent, Ader, Florence, Ferre, Virginie, Vicaut, Eric, Orain, Jéremie, Le Bras, Morgane, Omnes, Anne, Berly, Laetitia, Jobert, Alexandra, Morineau-Le Houssine, Pascale, Botturi, Karine, Josien, Régis, Flet, Laurent, Degauque, Nicolas, Brouard, Sophie, Duvaux, Odile, Poinas, Alexandra, and Raffi, François

Published
2021
Full Text
View/download PDF

4. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial

Author

Lortholary, Olivier, Roussillon, Caroline, Boucherie, Céline, Padoin, Christophe, Chaix, Marie-Laure, Breton, Guillaume, Rami, Agathe, Veziris, Nicolas, Patey, Olivier, Caumes, Eric, May, Thierry, Molina, Jean-Michel, Robert, Jérome, Tod, Michel, Fagard, Catherine, Chêne, Geneviève, Aumaître, H., Borsato, F., Malet, M., Médus, M., Moreau, L., Neuville, S., Saada, M., Abgrall, S., Ahoudji, D., Balmard, L., Bentata, M., Bouchaud, O., Boudribila, A., Cailhol, J., Dhote, R., Djebbar, R., Gros, H., Honoré, P., Huynh, T., Krivitzky, A., Mansouri, R., Pizzocolo, C., Rouges, F., Viot, E., Amar, B., Bantsimba, J., Dellion, S., Patey, O., Richier, L., Dupon, M., Dutronc, H., Neau, D., Ragnaud, J. M., Raymond, I., Boucly, S., Gailhoustet, L., Lortholary, O., Maignan, A., Touam, F., Viard, J. P., Bergmann, J. F., Boulanger, E., Delcey, V., Diemer, M., Durel, A., Jouade, F., Parrinello, M., Rami, A., Sellier, P., Brazille, P., Leclerc, C., Welker, Y., Bernard, L., Berthé, H., Perronne, C., Salomon, J., de Truchis, P., Bolliot, C., Couzigou, C., Derradji, O., Escaut, L., Teicher, E., Vittecoq, D., Chakvetadze, C., Fontaine, C., LʼYavanc, T., Maresca, A., Pialoux, G., Slama, L., Tuna, L., Bornarel, D., Boué, F., Chassaing, A., Chaiba-Berroukeche, L., Chambrin, V., Delavalle, A. M., Galanaud, P., Levy, A., Pignon, C., Bonnet, D., Ecobichon, J. L., Fournier, I., Fraquiero, G., Gerbe, J., Gervais, A., Guiyedi, V., Iordache, L., Joly, V., Klutse, P., Laurichesse, J. J., Leport, C., Onanga, M., Pahlaval, G., Phung, B. C., Ralaimazava, P., Yeni, P., Almasi, F., Basler, M., Benammar, N., Brunes, A., Guérin, C., Guillevin, L., Meddour, R., Salmon, D., Spiridon, G., Tahi, T., Bloch, M., Ferreira, C., Mahe, I., Manceron, V., Minozzi, C., Mortier, E., Simonpoli, A. M., Vinceneux, P., Zeng Ai, F., Chesnel, C., Dominguez, S., Jouve, P., Lascaux-Cametz, A. S., Lelièvre, J. D., Levy, Y., Melica, G., Sobel, A., Bentaleb, N., Blondin-Diop, A., Bonmarchand, M., Bossi, P., Brancon, C., Breton, G., Bricaire, F., Caby, F., Canestri, A., Clavel, C., Edeb, N., Herson, S., Iguertsira, M., Katlama, C., Kouadio, H., Lagarde, P., Lopez, J. L., Marguet, F., Martinez, V., Remidi, H., Simon, A., Souchon, J. F., Valantin, M. A., Bollens, D., Girard, P. M., Lagneau, J. L., Lefebvre, B., Mouchotte, R., Ouazene, Z., Sebire, M., Theveny-Christiany, A., Valin, N., Bourgarit, A., de Castro, N., Delgado, J., Ferret, S., Lascoux-Combe, C., Molina, J. M., Parlier, S., Pavie, J., Pintado, C., Ponscarme, D., Rachline, A., Sereni, D., Taulera, O., de Verdiere, C., Vincent, F., Bernard, N., Bonarek, M., Bonnet, F., Delaune, J., Lacoste, D., Louis, I., Malvy, D., Mercier, P., Morlat, P., Pertusa, M. C., Schottey, M., Chanteloube, N., Eden, A., Le Moing, V., Makilson, A., de Boever, C. Merle, Reynes, J., Turrière, C., Tramoni, C., Vidal, M., Anavena, C., Billaud, E., Biron, C., Bonnet, B., Bouchez, J., Boutoille, D., Brosseau, D., Brunct, C., Colas, M., Feuillebois, N., Hüe, H., Launay, E., le Houssine, P. Morineau, Raffi, F., Reliquet, V., Cua, E., Dellamonica, P., Durant, J., Rahelinirina, V., Arvieux, C., Chapplain, J. M., Fily, F., Labbay, E., Michelet, C., Morin, F., Peaucelle, C., Revest, M., Ratajczak, M., Souala, F., Tattevin, P., Thomas, R., Alvarez, M., Balsarin, F., Bonnet, E., Busato, F., Cuzin, L., Marche, D., Marchou, B., Massip, P., Obadia, M., Porte, L., Aissi, E., Ajana, F., Alcaraz, I., Baclet, V., Dubus, S., Gérard, Y., Guerroumi, H., Huleux, T., Lahouste, A., Marien, M. C., Melliez, H., Mouton, Y., Pennel, M. P., Valette, M., Viget, N., Yazdanpanah, Y., Bevilacqua, S., Boyer, L., Lecompte, T., Letranchant, L., May, T., Rabaud, C., Thomas, L., Vancon, R., Wassoumbou, S., Abboud, P., Borsa-Lebas, F., Caron, F., Debab, Y., Etienne, M., Faucon, M., Gueit, I., Brouqui, P., Mokhtari, S., Moreau, J., Schlojsers, M., Vandergheynst, E., Chousterman, M., Delacroix-Szmania, I., El Harrar, B., Garrait, V., Joannes, S., Luquet-Besson, I., Mouchet, M., Richier, L., Stevens, A. Blase, Dupont, C., Maresca, A. Freire, Greffe, S., Hanslik, T., Landi, B., Leporrier, J., Rouveix, E., Toth, K., El Mansouf, L., Khuong-Josses, M. A., Méchali, D., Le Besnerais, J. Phalip, Taverne, B., Barclay, F., Fain, O., Flexor, G., Stirnemann, J., Tassi, S., Levast, M., Rogeaux, O., Raffenot, D., Tous, J., Lortholary, O., Bouchaud, O., Chaix, M. L., Chêne, G., Couffin-Cadiergues, S., Dupon, M., Fagard, C., Joly, V., Launay, O., Molina, J. M., Robert, J., Roussillon, C., Rouzioux, C., Tod, M., Yazdanpanah, Y., Lortholary, O., Breton, G., Caumes, E., May, T., Roussillon, C., Veziris, N., Badets, M., Boucherie, C., Fagard, C., Chêne, G., Roussillon, C., Terras, N., Guérin, C., Altare, F., Bourgarit, A., Carcelain, G., Trylesinski, A., Aubron-Olivier, C., Nguyen, T., and Bennai, Y.

Published
2016
Full Text
View/download PDF

5. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission

Author

Chéret, Antoine, Bacchus-Souffan, Charline, Avettand-Fenoël, Veronique, Mélard, Adeline, Nembot, Georges, Blanc, Catherine, Samri, Assia, Sáez-Cirión, Asier, Hocqueloux, Laurent, Lascoux-Combe, Caroline, Allavena, Clotilde, Goujard, Cécile, Valantin, Marc Antoine, Leplatois, Anne, Meyer, Laurence, Rouzioux, Christine, Autran, Brigitte, Hoen, B., Bourdeaux, C., Delfraissy, J. F., Goujard, C., Amri, I., Fourn, E., Quertainmont, Y., Môle, M., Rami, A., Durel, A., Diemer, M., Parrinello, M., Allègre, T., Lafeuillade, A., Hittinger, G., Lambry, V., Carrerre, M., Philip, G., Duvivier, C., Consigny, P. H., Charlier, C., Shoai, M., Touam, F., Pialoux, G., Slama, L., LʼYavanc, T., Mathurin, P., Adda, A., Berrebi, V., Salmon, D., Chakvetadze, E., Tassadit, T., Ousseima, E., Pietri, M. P., Levy, Y., Lascaux, A. S., Lelievre, J. D., Giovanna, M., Dominguez, S., Dumont, C., Katlama, C., Valentin, M. A., Seang, S., Schneider, L., Kiorza, N., Chermak, A., Ben Abdallah, S., Simon, A., Pichon, F., Pauchard, M., Molina, J. M., Lascoux, C., Ponscarme, D., Colin De Verdiere, N., Scemla, A., De Castro, N., Rachline, A., Garrait, V., Rozenbaum, W., Ferret, S., Balkan, S., Clavel, F., Tourdjman, M., Lafaurie, M., Aslan, A., Goguel, J., Thierry, S. M., De Lastours, V., Gallien, S., Pavie, J., Delgado, J., Mededji, C., Veron, R., Abel, S., Pierre-François, S., Baringhton, C., Chennebault, J. M., Vandamme, Y. M., Fialaire, P., Rehaiem, S., Rabier, V., Abgueguen, P., Morlat, P., Vandenhende, M. A., Bernard, N., Lacoste, D., Michaux, C., Paccalin, F., Receveur, M. C., Caldato, S., Delaune, J., Ragnaud, J. M., Neau, D., Lacaze-Buzy, L., Livrozet, J. M., Jeanblanc, F., Makhloufi, D., Brunel Dalmas, F., Jourdain, J. J., Chiarello, P., Yeni, P., Phung, B., Rioux, C., Godard, C., Louni, F., El Alami Talbi, N., Catalano, G., Guiroy, F., Reynes, J., Jacquet, J. M., Fauchere, V., Merle, C., Lemoine, V., Loriette, M., Morquin, D., Makinson, A., Atoui, N., Tramoni, C., Raffi, F., Allavena, C., Bonnet, B., Bouchez, S., Feuillebois, N., Brunet-François, C., Reliquet, V., Mounoury, O., Morineau-Le-Houssine, P., Billaud, E., Brosseau, D., Hüe, H., Dellamonica, P., Vassallo, M., Leplatois, A., Durant, J., Naqvi, A., Joulié, A., Souala, F., Michelet, C., Arvieux, C., Tattevin, P., Leroy, H., Revest, M., Fily, F., Chapplain, J. M., Ratajczak, C. M., Gras, G., Bernard, L., Dailloux, J. F., Laplantine, V., Cuzin, L., Marchou, B., Larrigue, S., Chauveau, M., Balsarin, F., Obadia, M., Chéret, A., Bonne, S., Huleux, T., Ajana, F., Alcaraz, I., Baclet, V., Melliez, H., Viget, N., De La Tribonniere, X., Aissi, E., Poissy, J., Ravaux, I., Vallon, A., Varan, M., May, T., Letranchant, L., Burty, C., Briaud, A., Wassoumbou, S., Stenzel, M., Bouillon, M. P., Debab, Y., Caron, F., Gueit, I., Chapuzet, C., Borsa Lebas, F., Etienne, M., Miailhes, P., Perpoint, T., Senechal, A., Schlienger, I., Cotte, L., Augustin Normand, C., Boibieux, A., Ferry, T., Corsini, N., Braun, E., Lippran, J., Biron, F., Chidiac, C., Pailhes, S., Lipman, J., Braun, E., Koffi, J., Thoirain, V., Brochier, C., Greder Belan, A., Therby, A., Monnier, S., Ruquet, M., Garrait, V., Richier, L., Prevoteau Du Clary, F., Philibert, P., Chapus, C., Cabié, A., and Abel, S.

Published
2015
Full Text
View/download PDF

6. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial

Author

Pressiat, Claire, Hirt, Déborah, Treluyer, Jean-Marc, Zheng, Yi, Morlat, Philippe, Naqvi, Alice, Tran, Laurent, Viard, Jean-Paul, Avettand-Fenoel, Véronique, Rouzioux, Christine, Meyer, Laurence, Cheret, Antoine, Hoen, B, Bourdeaux, C, Delfraissy, J, Goujard, C, Amri, I, Fourn, E, Quertainmont, Y, Môle, M, Rami, A, Durel, A, Diemer, M, Parrinello, M, Allègre, T, Lafeuillade, A, Hittinger, G, Lambry, V, Carrerre, M, Philip, G, Duvivier, C, Consigny, P, Charlier, C, Shoai, M, Touam, F, Pialoux, G, Slama, L, l'Yavanc, T, Mathurin, P, Adda, A, Berrebi, V, Salmon, D, Chakvetadze, E, Tassadit, T, Ousseima, E, Pietri, M, Levy, Y, Lascaux, A, Lelievre, J, Giovanna, M, Dominguez, S, Dumont, C, Katlama, C, Valentin, M, Seang, S, Schneider, L, Kiorza, N, Chermak, A, Ben Abdallah, S, Simon, A, Pichon, F, Pauchard, M, Molina, J, Lascoux, C, Ponscarme, D, Colin de Verdiere, N, Scemla, A, de Castro, N, Rachline, A, Garrait, V, Rozenbaum, W, Ferret, S, Balkan, S, Clavel, F, Tourdjman, M, Lafaurie, M, Aslan, A, Goguel, J, Thierry, S, de Lastours, V, Gallien, S, Pavie, J, Delgado, J, Mededji, C, Veron, R, Abel, S, Pierre-François, S, Baringhton, C, Chennebault, J, Vandamme, Y, Fialaire, P, Rehaiem, S, Rabier, V, Abgueguen, P, Vandenhende, M, Bernard, N, Lacoste, D, Michaux, C, Paccalin, F, Receveur, M, Caldato, S, Delaune, J, Ragnaud, J, Neau, D, Lacaze-Buzy, L, Livrozet, J, Jeanblanc, F, Makhloufi, D, Brunel Dalmas, F, Jourdain, J, Chiarello, P, Yeni, P, Phung, B, Rioux, C, Godard, C, Louni, F, El Alami Talbi, N, Catalano, G, Guiroy, F, Reynes, J, Jacquet, J, Fauchere, V, Merle, C, Lemoine, V, Loriette, M, Morquin, D, Makinson, A, Atoui, N, Tramoni, C, Raffi, F, Allavena, C, Bonnet, B, Bouchez, S, Feuillebois, N, Brunet-François, C, Reliquet, V, Mounoury, O, Morineau-Le-Houssine, P, Billaud, E, Brosseau, D, Hüe, H, Dellamonica, P, Vassallo, M, Leplatois, A, Durant, J, Joulié, A, Souala, F, Michelet, C, Arvieux, C, Tattevin, P, Leroy, H, Revest, M, Fily, F, Chapplain, J, Ratajczak, C, Gras, G, Bernard, L, Dailloux, J, Laplantine, V, Cuzin, L, Marchou, B, Larrigue, S, Chauveau, M, Balsarin, F, Obadia, M, Bonne, S, Huleux, T, Ajana, F, Alcaraz, I, Baclet, V, Melliez, H, Viget, N, de la Tribonniere, X, Aissi, E, Poissy, J, Ravaux, I, Vallon, A, Varan, M, May, T, Letranchant, L, Burty, C, Briaud, A, Wassoumbou, S, Stenzel, M, Bouillon, M, Debab, Y, Caron, F, Gueit, I, Chapuzet, C, Borsa Lebas, F, Etienne, M, Miailhes, P, Perpoint, T, Senechal, A, Schlienger, I, Cotte, L, Augustin Normand, C, Boibieux, A, Ferry, T, Corsini, N, Braun, E, Lippran, J, Biron, F, Chidiac, C, Pailhes, S, Lipman, J, Koffi, J, Thoirain, V, Brochier, C, Greder Belan, A, Therby, A, Monnier, S, Ruquet, M, Richier, L, Prevoteau Du Clary, F, Evaluation thérapeutique et pharmacologie périnatale et pédiatrique (EA_7323), Université Paris Descartes - Paris 5 (UPD5), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Service de Maladies Infectieuses [CHU Nice], Hôpital l'Archet - CHU de Nice, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Diagnostic et de Thérapeutique, Hôpital de l’Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Service de Médecine Interne - Immunologie Clinique [AP-HP Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] (THERAVIR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and CHU Pontchaillou [Rennes]

Subjects
Male, 0301 basic medicine, MESH: Raltegravir Potassium, [SDV]Life Sciences [q-bio], HIV Infections, Pharmacology, Maraviroc, MESH: HIV-1, Plasma, chemistry.chemical_compound, Pharmacology (medical), MESH: Anti-HIV Agents, MESH: Maraviroc, Darunavir, MESH: Darunavir, education.field_of_study, MESH: Middle Aged, MESH: HIV Infections, Middle Aged, Viral Load, Infectious Diseases, MESH: Young Adult, Female, MESH: Viral Load, Viral load, medicine.drug, Adult, Microbiology (medical), Anti-HIV Agents, 030106 microbiology, Population, Emtricitabine, Young Adult, 03 medical and health sciences, Pharmacokinetics, Raltegravir Potassium, medicine, Humans, education, MESH: Plasma, Models, Statistical, Ritonavir, MESH: Humans, business.industry, MESH: Adult, Raltegravir, MESH: Male, 030104 developmental biology, chemistry, HIV-1, MESH: Ritonavir, business, MESH: Female, MESH: Models, Statistical
Abstract

International audience; BackgroundThe OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir and maraviroc) started early during primary HIV-1 infection with standard tritherapy with darunavir/ritonavir, tenofovir disoproxil fumarate and emtricitabine. From month 6 to 18, the percentage of viral load values

Published
2018
Full Text
View/download PDF

11. Rabid dog illegally imported to France from Morocco, August 2011

Author

Mailles, A, primary, Boisseleau, D, additional, Dacheux, L, additional, Michalewiscz, C, additional, Gloaguen, C, additional, Ponçon, N, additional, Bourhy, H, additional, Callon, H, additional, Vaillant, V, additional, Dabosville, I, additional, and Morineau-Le Houssine, P, additional

Published
2011
Full Text
View/download PDF

12. Prévalence élevée des lymphomes de la zone marginale chez les patients co-infectés VIH-VHC à l’ère de la trithérapie anti-virale : cohorte ANRS CO16 Lymphovir

Author

Terrier, B., primary, Cacoub, P., additional, Costagliola, D., additional, Chavez, H., additional, Canioni, D., additional, Escaut, L., additional, Letranchant, L., additional, Morineau-Le Houssine, P., additional, Simon, A., additional, Taoufik, Y., additional, Raphael, M., additional, and Besson, C., additional

Published
2010
Full Text
View/download PDF

14. Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure

Author

Raguin, Gilles, Chêne, Geneviève, Morand-Joubert, Laurence, Taburet, Anne-Marie, Droz, Cécile, Le Tiec, Clotilde, Clavel, François, Girard, Pierre-Marie, Rozenbaum, W, Naït-Ighil, L, Nguyen, TH, Slama, L, Girard, PM, Molina, JM, Sereni, D, Colin de Verdière, N, Lascoux-Combes, C, Pintado, C, Ponscarme, D, Prevoteau de Clary, F, Tourneur, M, Bentata, M, Guillevin, L, Launay, O, Mansouri, R, Rouges, F, Kazatchkine, M, Aouba, A, Azizi, M, Fiessinger, JN, Le Houssine, P, Sicard, D, Bernasconi, C, Salmon, D, Silbermann, B, Cassuto, JP, Ceppi, C, Poiree, Dr, Raguin, G, Merad, M, Delfraissy, JF, Goujard, C, Quertainmont, Y, Perronne, C, de Truchis, P, Dupont, B, Bresson, JL, Calatroni, I, Raffi, F, Esnault, JL, and Leautez, S

Abstract

Objectives To compare the antiviral efficacy of a salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple anti-retroviral regimens had failed.Design Phase IIb, randomized, open-label, multicentre trial. Patients were eligible if they had <500 CD4+ cells/mm3and >4 log10copies/ml HIV-RNA after treatment with at least two protease inhibitors (PIs) and one non-nucleoside reverse transcriptase inhibitor.Results At baseline (n=37), the median CD4+ cell count was 207/mm3and the median plasma HIV-1 RNA level was 4.7 log10copies/ml; the median number of PI mutations was seven and the median decrease in phenotypic susceptibility to lopinavir and amprenavir was 9.7 and 2.6, respectively. The mean number of antiretrovirals received prior to randomization was 7.7. The fall in the median HIV-1 RNA level at week 26 was -1.4 log10copies/ml in the 200 mg/d ritonavir group and -2.5 log10copies/ml in the 400 mg/d group (P=0.02). Viral load fell below 50 copies/ml in 32% and 61% of patients, respectively (P=0.07). After adjustment for the ritonavir dose, a smaller number of PI mutations was the only baseline characteristic associated with a better virological response at week 26. Amprenavir concentrations were significantly lower in presence of lopinavir. The lopinavir inhibitory quotient at week 6 correlated weakly with the change in the HIV-RNA level at week 26.Conclusion Combination of amprenavir, lopinavir and 400 mg/d ritonavir shows significant virological efficacy without increased toxicity in HIV-infected patients in whom multiple antiretroviral regimens have failed.

Published
2004
Full Text
View/download PDF

15. Assessement of Awareness of, Concerns and Attitudes Towards HIV-Related Court-Case Sentences in France in a Representative Sample of People Living with HIV (ANRS VESPA2 Survey)

Author

Marie Suzan-Monti, Bruno Spire, Antoine Vilotitch, Rosemary Dray-Spira, Patrick Yeni, Michel Celse, Baptiste Demoulin, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Conseil national du sida et des hépatites virales [Paris, France], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), The VESPA2 survey was sponsored and funded by the French National Agency for Research on Aids and Viral Hepatitis (ANRS), Grant No. 2010-176., ANRS VESPA2 study group : Lert F, Spire B, Carrieri P, Dray-Spira R, Hamelin C, Lorente N, Préau M, Suzan-Monti M, Mora M, Le Strat Y, Cuzin L, Meyer L, Rojas-Castro D, Fischer H, Allègre T, Mours P, Riou JM, Sordage M, Chennebault JM, Fialaire P, Rabier V, Froidure M, Huguet D, Leduc D, Pichancourt G, Wajsbrot A, Bourdeaux C, Foltzer A, Hoen B, Hustache-Mathieu L, Abgrall S, Barruet R, Bouchaud O, Chabrol A, Mattioni S, Mechai F, Jeantils V, Bernard N, Bonnet F, Hessamfar M, Lacoste D, Malvy D, Mercié P, Morlat P, Paccalin F, Pertusa MC, Pistone T, Receveur MC, Vandenhende MA, Dupont C, Freire Maresca A, Leporrier J, Rouveix E, Dargere S, de la Blanchardière A, Martin A, Noyon V, Verdon R, Rogeaux O, Beytout J, Gourdon F, Laurichesse H, Meier F, Mortier E, Simonpoli AM, Cordier F, Delacroix I, Garrait V, Elharrar B, Dominguez S, Lascaux AS, Lelièvre JD, Levy Y, Melica G, Buisson M, Piroth L, Waldner A, Gruat N, Leprêtre A, de Truchis P, Le Du D, Melchior JC, Sehouane R, Troisvallets D, Blanc M, Boccon-Gibod I, Bosseray A, Brion JP, Durand F, Leclercq P, Marion F, Pavese P, Brottier-Mancini E, Faba L, Roncato-Saberan M, Bollengier-Stragier O, Esnault JL, Leautez-Nainville S, Perré P, Froguel E, Nguessan M, Simon P, Colardelle P, Doll J, Godin-Collet C, Roussin-Bretagne S, Delfraissy JF, Duracinsky M, Goujard C, Peretti D, Quertainmont Y, Marionneau J, Aissi E, Van Grunderbeeck N, Denes E, Ducroix-Roubertou S, Genet C, Weinbreck P, Augustin-Normand C, Boibieux A, Cotte L, Ferry T, Koffi J, Miailhes P, Perpoint T, Peyramond D, Schlienger I, Brunel JM, Carbonnel E, Chiarello P, Livrozet JM, Makhloufi D, Dhiver C, Husson H, Madrid A, Ravaux I, de Severac ML, Thierry Mieg M, Tomei C, Hakoun S, Moreau J, Mokhtari S, Soavi MJ, Faucher O, Ménard A, Orticoni M, Poizot-Martin I, Atoui N, Baillat V, Faucherre V, Favier C, Jacquet JM, Le Moing V, Makinson A, Mansouri R, Merle C, Elforzli N, Allavena C, Aubry O, Besnier M, Billaud E, Bonnet B, Bouchez S, Boutoille D, Brunet C, Feuillebois N, Lefebvre M, Morineau-Le Houssine P, Mounoury O, Point P, Raffi F, Reliquet V, Talarmin JP, Ceppi C, Cua E, Dellamonica P, De Salvador-Guillouet F, Durant J, Ferrando S, Mondain-Miton V, Perbost I, Pillet S, Prouvost-Keller B, Pradier C, Pugliese P, Rahelinirina V, Roger PM, Rosenthal E, Sanderson F, Hocqueloux L, Niang M, Prazuck T, Arsac P, Barrault-Anstett MF, Ahouanto M, Bouvet E, Castanedo G, Charlois-Ou C, Dia Kotuba A, Eid-Antoun Z, Jestin C, Jidar K, Joly V, Khuong-Josses MA, Landgraf N, Landman R, Lariven S, L'hériteau F, Machado M, Matheron S, Michard F, Morau G, Pahlavan G, Phung BC, Prévot MH, Rioux C, Yéni P, Bani-Sadr F, Calboreanu A, Chakvetadze E, Salmon D, Silbermann B, Batisse D, Beumont M, Castiel P, Derouineau J, Eliaszewicz M, Gonzalez G, Jayle D, Karmochkine M, Kousignian P, Pavie J, Pierre I, Weiss L, Badsi E, Bendenoun M, Cervoni J, Diemer M, Durel A, Rami A, Sellier P, Ait-Mohand H, Amirat N, Bonmarchand M, Bourdillon F, Breton G, Caby F, Grivois JP, Katlama C, Kirstetter M, Paris L, Pichon F, Roudière L, Schneider L, Samba MC, Seang S, Simon A, Stitou H, Tubiana R, Valantin MA, Bollens D, Bottero J, Bui E, Campa P, Fonquernie L, Fournier S, Girard PM, Goetschel A, Guyon HF, Lacombe K, Lallemand F, Lefebvre B, Maynard JL, Meyohas MC, Ouazene Z, Pacanowski J, Picard O, Raguin G, Roussard P, Tourneur M, Tredup J, Valin N, Balkan S, Clavel F, de Verdière NC, De Castro N, de Lastours V, Ferret S, Gallien S, Gérard L, Goguel J, Lafaurie M, Lascoux-Combe C, Molina JM, Oksenhendler E, Pintado C, Ponscarme D, Rozenbaum W, Scemla A, Bonnard P, Lassel L, Lebrette MG, Lyavanc T, Mariot P, Missonnier R, Ohayon M, Pialoux G, Treilhou MP, Vincensini JP, Gilquin J, Hadacek B, Nait-Ighil L, Nguyen TH, Sobel A, Viard JP, Zak Dit Zbar O, Aumaître H, Eden A, Ferreyra M, Lopez F, Medus M, Neuville S, Saada M, Blum L, Perfezou P, Arvieux C, Chapplain JM, Revest M, Souala F, Tattevin P, Bord S, Borsa-Lebas F, Caron F, Chapuzet C, Debab Y, Gueit I, Etienne M, Fartoukh C, Feltgen K, Joly C, Robaday-Voisin S, Suel P, Khuong MA, Krausse J, Poupard M, Tran Van G, Cazorla C, Daoud F, Fascia P, Frésard A, Guglielminotti C, Lucht F, Bernard-Henry C, Cheneau C, Lang JM, de Mautort E, Partisani M, Priester M, Rey D, Majerholc C, Zucman D, Assi A, Lafeuillade A, de Jaureguiberry JP, Gisserot O, Aquilina C, du Clary FP, Alvarez M, Chauveau M, Delobel P, Garipuy D, Labau E, Marchou B, Massip P, Mularczyk M, Obadia M, Ajana F, Allienne C, Baclet V, de la Tribonnière X, Huleux T, Melliez H, Meybeck A, Riff B, Valette M, Viget N, Bastides F, Bernard L, Gras G, Guadagnin P, May T, Rabaud C, Dos Santos A, Poinsignon Y, Derradji O, Escaut L, Teicher E, Vittecoq D, Bantsima J, Caraux-Paz P, Patey O., Lissalde, Claire, and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Social Psychology, Social stigma, Cross-sectional study, Social Stigma, Stigma (botany), HIV Infections, 03 medical and health sciences, Discrimination, Psychological, 0302 clinical medicine, Criminalization, 5. Gender equality, Criminal Law, Surveys and Questionnaires, medicine, Humans, 030212 general & internal medicine, 10. No inequality, Psychiatry, Prejudice (legal term), Transients and Migrants, Depressive Disorder, Major, Stereotyping, 030505 public health, Public health, Public Health, Environmental and Occupational Health, HIV, Awareness, Middle Aged, 16. Peace & justice, Health psychology, Cross-Sectional Studies, Sexual Partners, Infectious Diseases, Attitude, Socioeconomic Factors, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Criminal law, Female, Key population, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, 0305 other medical science, Psychology, Prejudice
Abstract

International audience; Some of the 12 criminal trials and sentences in France for HIV transmission in 1998-2011 attracted substantial public attention , with a possible negative impact on people living with HIV (PLWH) through reinforced stigma and discrimination. This analysis aimed to characterize PLWH enrolled in the representative ANRS-VESPA2 survey, aware of and concerned about convictions for HIV transmission. Being a migrant from Sub-Saharan Africa, having difficult socioeconomic conditions, having unprotected sex with one's main partner and concealing one's HIV status were all factors statistically associated with concern about the sentences. Participants tempted to press charges against someone for infecting them were more likely to be younger, women, not living in a couple, unemployed, and to report a major depressive disorder. Concern about HIV-related criminal proceedings among the most vulnerable PLWH do not reflect the actual risk of prosecution they are exposed to. Resumen En Francia, algunos de los 12 juicios y sentencias relacionados con la contaminación del VIH en 1998-2011 suscitaron con-siderablemente el interés público. Esto pudo impactar negativamente las personas viviendo con VIH (PVVIH) aumentando su estigmatización y discriminación. Este análisis busca caracterizar las PVVIH, de la encuesta ANRS-VESPA2, informadas acerca de esos juicios e inquietos por la posibilidad de implicación en uno de ellos. Ser inmigrante subsahariano, las con-diciones socio-económicas desfavorables, las relaciones sexuales no protegidas con la pareja principal, y ocultar el VIH, están asociados a la posibilidad de ser implicados en un juicio. Por otro lado, aquellos que han intentado presentar cargos por contaminación del VIH fueron mayoritariamente jóvenes, mujeres, personas viviendo solas, desempleados, y personas en depresión. Los juicios por contaminación del VIH entre las PVVIH más vulnerables no reflejan el riesgo de acusación al que están expuestos.

Published
2018
Full Text
View/download PDF

16. Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies.

Author

Parize P, Poujol P, Morineau Le Houssine P, Goesch J, Lucet C, Basuyau L, Cailhol J, Dacheux L, Bourhy H, and Consigny PH

Subjects
Humans, Immunity, Post-Exposure Prophylaxis, Retrospective Studies, Immunologic Deficiency Syndromes, Rabies prevention & control, Rabies Vaccines
Abstract

Background: This study sought to determine the proportion of individuals with non-HIV secondary immunodeficiencies presenting inadequate antibody titers after rabies post-exposure prophylaxis (PEP) and to identify variables associated with inadequate response., Methods: A retrospective review of the records of immunocompromised patients having received a full course of PEP after a rabies exposure and having been tested for post-PPE antibody titers in two French Antirabies Clinics, between 2013 and 2018, was conducted. Antibody titers < 0.5 EU/ml (ELISA) were classified as inadequate., Results: A total of 28 individuals were included, 6 had inadequate post-PPE titers. None of the tested variable was independently associated with inadequate titers., Conclusions: Inadequate response was unpredictable and not explained either by the characteristics of patients or by the PEP regimen they received. These findings support the WHO recommendation to systematically assess post-PEP response in immunocompromised patients to detect non-responders, who might require an additional dose., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Ltd. All rights reserved.)

Published
2020
Full Text
View/download PDF

17. Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study.

Author

Terrier B, Costagliola D, Prevot S, Chavez H, Missy P, Rince P, Costello R, Escaut L, Gabarre J, Joly B, Letranchant L, Le Gouill S, Morineau-Le Houssine P, Simon A, Canioni D, Hermine O, Cacoub P, Taoufik Y, Raphael M, and Besson C

Subjects
Adult, Aged, Antibodies, Viral immunology, Cohort Studies, Coinfection, Female, HIV Infections drug therapy, HIV Infections immunology, HIV Infections virology, Hepacivirus immunology, Hepatitis C drug therapy, Hepatitis C immunology, Hepatitis C virology, Humans, Lymphoma, AIDS-Related immunology, Lymphoma, B-Cell complications, Lymphoma, B-Cell immunology, Lymphoma, B-Cell, Marginal Zone complications, Male, Middle Aged, Prospective Studies, Viral Load, Anti-HIV Agents therapeutic use, Antibodies, Viral blood, HIV Infections complications, Hepatitis C complications, Lymphoma, AIDS-Related complications, Lymphoma, B-Cell virology
Abstract

Hepatitis C virus (HCV) infection is frequent among HIV-infected patients. We describe, the characteristics of 6 HIV/HCV-coinfected patients with B-cell non-Hodgkin lymphoma (NHL) included in a prospective cohort study of HIV-related lymphomas. Five of the 6 cases had features of marginal zone/lymphoplasmacytic NHL versus 1 of 33 HIV only-infected patients. Remarkably, anti-HCV treatment led to a hematological response in a patient with splenic marginal zone lymphoma. This supports the role of chronic antigenic stimulation by HCV on lymphomagenesis and further evaluation of HCV antiviral therapy in coinfected patients with NHL.

Published
2013
Full Text
View/download PDF

18. [Primary pulmonary hypertension in human immunodeficiency virus infection. Study of 9 cases amd review of the literature].

Author

Le Houssine P, Karmochkine M, Ledru F, Batisse D, Piketty C, Kazatchkine MD, and Weiss L

Subjects
Adult, Anti-HIV Agents therapeutic use, Female, Follow-Up Studies, HIV Infections diagnosis, HIV Infections drug therapy, Hemodynamics, Humans, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary physiopathology, Male, Middle Aged, Prospective Studies, Retrospective Studies, Substance Abuse, Intravenous complications, Time Factors, HIV Infections complications, Hypertension, Pulmonary etiology
Abstract

Purpose: In medical literature, primary pulmonary hypertension occurs in 0.5% of human immunodeficiency virus (HIV)-infected patients, irrespective of the stage of the HIV disease, and is more frequent in drug users. Plexogenic arteriopathy is the most frequent histological lesion., Methods: We retrospectively report on nine cases of primary pulmonary hypertension during HIV infection., Results: The subjects were four women and five men, mean age 38 years old. Four of them had been sexually contaminated and five had contracted the disease through intravenous drug use. At the time primary pulmonary hypertension was diagnosed, mean CD4 cell count was 234 +/- 217/mm3 and the viral load was low or undetectable. Primary pulmonary hypertension has been diagnosed an average of 7 months after the first cardiovascular clinical signs had started. Despite anti-coagulant (7/9 cases), vasodilatator (4/9 cases) and/or diuretic (7/9 cases) therapy, the progression of the disease quickly turned out to be negative (seven deaths)., Conclusion: Diagnosis of primary pulmonary hypertension should be considered when unexplained dyspnea occurs in an HIV-positive patient. At initial evaluation, alterations of hemodynamic parameters are usually less severe than during idiopathic primary pulmonary hypertension, but their progression is quicker and more severe, independent of the patient's immune status. Current data do not allow the determination of whether antiretroviral therapy is active in primary pulmonary hypertension evolution. Therapeutic evaluation with prostacyclin is currently being carried out. While the life expectancy of HIV-infected patients extends, primary pulmonary hypertension occurrence could increase and call for early diagnosis, thus allowing for specific care.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results